The US Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults ...

The new drug type targets pathways in the peripheral nervous system before pain signals reach the brain, potentially lowering ...

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday's market open after the Food and Drug Administration approved the company's non-opioid pain treatment.

U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...

Shares of Vertex Pharmaceuticals rose 8% in off-hours trading after the pharmaceutical company won U.S. approval for the [first new non-opioid painkiller in decades]( ...

The pharma major beat analysts' expectations in the fourth quarter of 2024, despite looming competition for its top heart drug Entresto. The watchdog blocked access to DeepSeek after the companies ...

Apple stock rises after the tech giant posts better-than-expected earnings and guides for solid growth, while Intel’s ...

Vertex Pharmaceuticals' newly FDA-approved non-opioid analgesic, Journavx, offers a groundbreaking alternative for managing ...

The Food and Drug Administration on Tuesday approved Journavx, the first drug in a new class of non-opioid pain medications, ...

Vertex Pharmaceuticals (VRTX) announced a reimbursement agreement with NHS England for eligible sickle cell disease patients to access the ...